SCHOTT Pharma has opened a new production facility for high-quality prefillable glass syringes in Hungary.
 
Supported by a EUR 9 million ($9.7 billion) investment from the local government, SCHOTT Pharma is expanding its global capacities for strategically important high-value solutions that address key pharma trends. At the same time, the company is strengthening its competitiveness in Europe and the supply security for major pharmaceutical companies and contract manufacturing organizations.
 
To supply the fast and dynamically growing market, SCHOTT Pharma plans to further invest a multi-million Euro amount in Hungary in prefillable syringes in the near future.
 
“With an increasing number of drugs being stored in prefillable glass syringes – from GLP-1 drugs to critical vaccines and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the pharma industry,” says Andreas Reisse, CEO of SCHOTT Pharma.
 
As evidenced by their growing demand in the healthcare industry, these high-quality prefillable glass syringes not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians.
 
SCHOTT Pharma’s Hungarian site, which was inaugurated in Lukácsháza today, builds on the company’s existing foundation and pharmaceutical production skillset in the area, which already plays an important role in supplying the global industry with drug containment systems today.
 
The facility is equipped with state-of-the-art machinery and is the second site where the company manufactures glass syringes, in addition to the site in St. Gallen, Switzerland.